1	Long-term clinical and patient reported outcomes of an
2	enhanced monofocal intraocular lens
3	
4	
5	Catharina Latz <sup>1*</sup> , Annika Licht <sup>1</sup> , Katharina A. Ponto <sup>1,2</sup> , Johannes Menzel-Severing <sup>1,3</sup> ,
6	David P. Piñero <sup>4</sup> , Alireza Mirshahi <sup>1</sup>
7	
8	<sup>1</sup> Dardenne Eye Hospital, Bonn, Germany, Germany
9	<sup>2</sup> Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany
10	<sup>3</sup> Department of Ophthalmology, University of Düsseldorf, Düsseldorf, Germany
11	<sup>4</sup> Department of Optics, Pharmacology and Anatomy, University of Alicante, Sant Vicent
12	del Raspeig, Alicante, Spain
13	
14	* Corresponding author
15	E-mail: c_latz@hotmail.com
16	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 17 Abstract

18 Purpose: To evaluate long-term clinical and patient-reported outcomes (PROMs)19 following the implantation of an enhanced monofocal intraocular lens (IOL).

Methods: This ambispective non-comparative single-centre study involved 41 patients (ages 48-84) who underwent bilateral cataract surgery with the Tecnis Eyhance IOL (model ICB00, Johnson & Johnson Vision). Distance and intermediate visual acuities, refraction, and PROMs were assessed 18 months or more after surgery. Spectacle independence was evaluated using the PRSIQ questionnaire, with patients self-reporting on visual quality, difficulties in performing specific tasks and perception of photic phenomena at distance and intermediate vision.

27 Results: At 18 months or later, 100.0%, 73.2%, 100% and 79.5% of patients achieved a binocular uncorrected distance, uncorrected intermediate, corrected distance, and 28 distance-corrected intermediate visual acuity of 0.20 logMAR or better, respectively. 29 Less than 10% of patients reported photic phenomena. Mean visual quality scores were 30 1.68±0.72 for distance and 2.05±0.92 for intermediate vision (1=very good to 6=very 31 32 poor). The dashboard was clearly visible while driving for 95.1% of patients, while 45.0% could perform screen work without glasses; an additional 40.0% could do so with 33 enlarged fonts. Complete spectacle independence was reported by 87.8% for distance 34 vision, and 53.7% for intermediate vision. At least moderately satisfied were 90.2% with 35 distance vision, 87.8% with intermediate vision, and 51.2% with near vision. 36

37 Conclusions: The enhanced monofocal IOL ICB00 provides good long-term distance
38 and intermediate visual quality, leading to considerable spectacle independence and
39 patient satisfaction. Most patients required near vision correction.

## 40 Introduction

Presbyopia-correcting IOLs can be categorized by their underlying optical-41 42 physical properties into diffractive and non-diffractive IOLs. While diffractive IOLs split incoming light through surface discontinuities, non-diffractive IOLs bend light by surface 43 curvature changes. Another way to categorize IOLs is the range of focus they offer. Full 44 range of focus (FROF) IOLS cover vision from distance to near, including intermediate 45 distances. Due to their typically diffractive technology, PROF IOLs may compromise 46 47 visual experience through dysphotopsia. Partial range of focus (PROF) IOLs cover a partial spectrum of vision, typically extending from distance to intermediate, with some 48 49 capacity for near vision. They may be diffractive and non-diffractive and create fewer 50 visual compromises such as dysphotopsias. Most recently, Fernandez et al. offered a systematic approach to categorize IOL types based on the shape of the defocus curve: 51 PROF IOLs were divided into narrow, enhanced and extended PROF IOLs<sup>1</sup>. 52

In 2018, the American National Standard Institute (ANSI) provided specific 53 criteria to define enhanced depth of focus (EDOF) IOLs as IOLs that correct aphakia, 54 55 with an extended range of focus above a defined functional visual acuity threshold of 0.2 LogMAR, providing useful distance and intermediate vision with monotonically 56 decreasing visual acuity from the best distance focal point.<sup>2</sup> With the introduction of a 57 new technology named Tecnis Eyhance (model ICB00, Johnson & Johnson Vision) in 58 2019, a new category of intraocular lenses (IOLs) was generated, popularly known as 59 mono-EDOF, or enhanced monofocal IOLs.<sup>3</sup> According to Fernandez et al<sup>1</sup> this IOL 60 61 would be classified as enhanced PROF. This IOL extends the depth of focus similarly to EDOF IOLs, but does not meet the four effectiveness end-points required to classify it as 62 true EDOF lenses according to the criteria of the American National Standard Z80.35-63 2018 (ANSI).<sup>2</sup> Enhanced monofocal IOLs include some optical modifications to provide 64

an efficacious correction for distance vision while providing an enhanced intermediate
visual function. Various studies have been conducted to characterize the clinical
performance and patient acceptance of the Eyhance IOL and other enhanced monofocal
IOLs.<sup>3-5</sup> Notably, no higher incidence of postoperative photic phenomena was reported
with these IOLs compared to regular monofocal lenses.<sup>6</sup>

The Evhance ICB00 IOL has an aspherical posterior surface and a modified 70 71 aspheric anterior surface with a continuous increase in power from the periphery to the center of the lens while maintaining the distance image quality.<sup>7</sup> The overall lens design 72 is refractive and leverages the geometry, material, and corneal spherical aberration 73 74 correction features, with a higher order aspheric profile included on the anterior optic surface. As this lens is designed to retain the benefits of a monofocal IOL while adding 75 intermediate vision, the ICB00 IOL is considered an "enhanced" monofocal IOL designed 76 77 to provide improved intermediate vision.<sup>7</sup> A variety of clinical studies have demonstrated that this IOL provides good distance visual acuity with enhanced intermediate visual 78 79 acuity.<sup>8-27</sup> Specifically, enhanced monofocal IOLs provide comparable results in terms of distance vision compared to conventional monofocal IOLs.<sup>8-27</sup> However, the number of 80 studies about patient-reported outcomes (PROMs), which reflect the real perception of 81 82 the patient regarding the improvement achieved with the implantation of the IOL, is still limited.7,11,17,27 Furthermore, long-term real-world data is still scarce. Given that 83 neuroadaptation and habituation are the basis for patient satisfaction with all refractive 84 85 IOLs and that this process takes 6 months and longer, it is of particular interest to analyze patient-reported outcomes at long term. Also, to satisfactorily manage patient 86 expectations, it is especially relevant to know the real level of spectacle independence 87 achieved with this type of enhanced monofocal IOL. The aim of the current study was to 88 evaluate the long-term clinical and patient-reported outcomes after the implantation of 89

the enhanced monofocal IOL ICB00 with special emphasis on the achieved level of
spectacle independence. In addition, patient satisfaction with this type of IOL in a realworld setting was analyzed.

## 93 Methods

#### 94 **Patients**

This was an ambispective, non-comparative, single-centre study enrolling a total 95 of 41 patients who underwent uncomplicated phacoemulsification bilateral cataract 96 97 surgery with implantation of the enhanced monofocal IOL ICB00 and had a follow up visit of 18 months or longer. Recruitment stared on October 17,2023 and ended November 98 99 30<sup>th</sup> 2023. The last patient was examined on December 12<sup>th</sup>, 2023. Included were patients 100 with both eves having a corneal astigmatism below 0.75D, aged 45 or older, and visually significant cataract. Exclusion criteria included known systemic diseases with the 101 102 potential of altering the outcome of the study, previous ocular surgery including refractive 103 surgery, irregular astigmatism, zonular alterations that may affect IOL position and stability, active ocular disease, previous diagnosis of retinal pathologies and severe 104 105 glaucoma, as defined by mean deviation deficits of more than 12 dB on visual fields.

Before inclusion in the study, each patient was informed in detail about the nature of the study, and written informed consent was given according to the tenets of the Declaration of Helsinki. Minors were not included in the study. This study was approved by the medical ethics committee of the Medical Chamber of North-Rhine, Germany (No: 2023012).

#### 111 Clinical Protocol

112 All patients underwent a complete preoperative examination, including 113 measurement of uncorrected distance visual acuity (UDVA) and corrected distance visual 114 acuity (CDVA), objective refraction by autorefractometry, optical biometry and

keratometry (IOLMaster 700, Carl Zeiss Meditec), non-contact tonometry, slit lamp 115 116 biomicroscopy, optical coherence tomography of the macula and optic disc (Carl Zeiss Meditec), and dilated fundus evaluation. In all cases, the Barrett TK formula was used for 117 IOL power calculation, targeting emmetropia. 118 Postoperatively, patients were evaluated at 1 day and later at the discretion of the referring 119 120 physician. Eighteen months after cataract surgery, all patients were contacted by phone 121 and/or email and scheduled for a long-term follow-up visit. At this visit, a complete visual 122 evaluation was performed, including the following tests: monocular and binocular measurement of UDVA and CDVA, manifest refraction, and measurement of uncorrected 123 124 intermediate visual acuity (UIVA) and distance-corrected intermediate visual acuity

(DCIVA) (measured at 66 cm). Spectacle independence was evaluated using the PatientReported Spectacle Independence Questionnaire (PRSIQ).<sup>28</sup> We assessed the patientreported quality of vision and photic phenomena using a self-developed questionnaire,
where patients quantified the level of distance and intermediate visual quality on a scale
from 1 (excellent) to 6 (extremely poor). Additionally, patients were asked about the
perception of halos, glare, blurring, and starbursts at distance and intermediate vision.

#### 131 Surgery

All surgeries were performed by two experienced surgeons (AM, KT) using a standard technique of sutureless microincision phacoemulsification. Before surgery, patients received a peribulbar block (4 mL 0.75% bupivacaine, 2 mL 2% mepivacaine and 75 IE hyaluronidase (ESTEVE Pharmaceuticals GmbH) and dilating eye drops (phenylephrine hydrochloride 5%, Ursapharm Arzneimittel GmbH; tropicamide 0.5%,

Pharma Stulln GmbH). Patients who were taking warfarin with a high internationalnormalized ratio received topical anesthesia.

A clear corneal incision with a width of 2.4 mm was placed either superior or 139 temporal as well as two paracenteses (1.0 mm). A manual capsulorhexis was performed 140 under ophthalmic viscoelastic device (OVD). Care was taken to achieve a capsulorhexis 141 diameter of approximately 5 mm to ensure complete coverage of the IOL optic with the 142 143 anterior capsule. Nuclear disassembly and cortical aspiration were performed using the Centurion vision system (Alcon). The IOL was delivered either under irrigation or 144 145 viscoelastic protection with an injector provided by the manufacturer. At the end of the 146 procedure, 1 mg cefuroxime and 2mg dexamethasone [4 mg/mL] were administered intracamerally and subconjunctivally, respectively. 147

Postoperative treatment included a combination eye drop four times a day containing dexamethasone, neomycin sulfate, and polymyxin-B-sulfate with ointment at night or, in case of allergies to preservatives, ofloxacin and dexamethasone eyedrops four times a day. This treatment was tapered over 4 weeks.

#### 152 Statistical analysis

Data analysis was performed using the software SPSS version 22.0 for Windows (SPSS). Normality of all data distributions was initially evaluated by means of the Kolmogorov-Smirnov test. A descriptive analysis of all continuous variables was carried out, calculating the average values with their corresponding standard deviations and the ranges of maximum and minimum values. For categorical variables, frequencies of different conditions or aspects were determined. A p-value below 0.05 was considered statistically significant.

### 160 **Results**

Patient population: A total of 82 eyes of 41 patients with a mean age of 69.4 years
(SD: 9.0, median: 70.0, range: 48 to 84 years) was enrolled. The sample comprised 24
males (58.5%) and 17 females (41.5%).
Refractive outcomes: Table 1 summarizes the visual and refractive outcomes
obtained at the last postoperative visit, more than 18 months after surgery: Mean
postoperative binocular logMAR UDVA and UIVA values were 0.05 ± 0.07 and 0.18 ±

168

167

0.12, respectively.

	<b>Right</b> eye	Left eye	Binocular
VA (LogMar)	Mean (SD)	Mean (SD)	Mean (SD)
	Median (Range)	Median (Range)	Median (Range)
UDVA	0.11 (0.10)	0.10 (0.09)	0.05 (0.07)
	0.10 (0.00 to 0.30)	0.10 (0.00 to 0.30)	0.00 (0.00 to 0.20)
CDVA	0.05 (0.08)	0.04 (0.05)	0.02 (0.04)
	0.00 (0.00 to 0.30)	0.00 (0.00 to 0.20)	0.00 (0.00 to 0.10)
UIVA	0.27 (0.15)	0.24 (0.14)	0.18 (0.12)
	0.30 (0.00 to 0.70)	0.20 (0.00 to 0.60)	0.20 (0.00 to 0.50)
DCIVA	0.22 (0.13)	0.22 (0.13)	0.17 (0.11)
	0.20 (0.00 to 0.50)	0.20 (0.00 to 0.50)	0.20 (0.00 to 0.40)
SE (D)	0.06 (0.47)	0.19 (0.53)	
	0.00 (-0.75 to 1.13)	0.25 (-1.00 to 1.50)	

169

Table 1.- Long-term (18 months or longer) postoperative visual and refractive
outcomes: CDVA, corrected distance visual acuity; DCIVA, distance-corrected
intermediate visual acuity; SD, standard deviation; SE, spherical equivalent; UDVA,
uncorrected distance visual acuity; UIVA, uncorrected intermediate visual acuity.

<b>T</b> 1 <b>d</b>	1	7	4
---------------------	---	---	---

±/ ·	
175	Likewise, a mean binocular logMAR DCIVA value of 0.17 $\pm$ 0.11 was measured.
176	100.0%, 73.2%, 100% and 79.5% of patients achieved a binocular UDVA, UIVA, CDVA
177	and DCIVA of 0.20 logMAR or better, respectively (Figure 1).
178	
179	Figure 1 Postoperative binocular visual acuity: uncorrected distance (UDVA),
180	uncorrected intermediate (UIVA), corrected distance (CDVA) and distance-corrected
181	intermediate (DCIVA).
182	
183	The postoperative spherical equivalent (SE) was within $\pm 0.50$ D in 80.5% of right eyes
184	and 82.9% of left eyes. Likewise, postoperative SE was within $\pm 1.00$ D in 95.1% and
185	92.7% of right and left eyes, respectively.
186	
187	Patient-reported outcome measurements: PRSIQ and our own developed
187 188	<b>Patient-reported outcome measurements:</b> PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported
187 188 189	<b>Patient-reported outcome measurements:</b> PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of
187 188 189 190	<b>Patient-reported outcome measurements:</b> PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of patients reported the perception of halos, blurry vision, and glare at distance vision,
187 188 189 190 191	<b>Patient-reported outcome measurements:</b> PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of patients reported the perception of halos, blurry vision, and glare at distance vision, respectively (Figure 2).
187 188 189 190 191 192	<b>Patient-reported outcome measurements:</b> PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of patients reported the perception of halos, blurry vision, and glare at distance vision, respectively (Figure 2).
187 188 189 190 191 192 193	Patient-reported outcome measurements: PRSIQ and our own developed         questionnaire were used to assess PROMs: A small percentage of patients reported         postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of         patients reported the perception of halos, blurry vision, and glare at distance vision,         respectively (Figure 2).         Figure 2 Perception of photic phenomena 18 months postoperatively.
187 188 189 190 191 192 193 194	Patient-reported outcome measurements: PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of patients reported the perception of halos, blurry vision, and glare at distance vision, respectively (Figure 2). Figure 2 Perception of photic phenomena 18 months postoperatively.
187 188 189 190 191 192 193 194 195	<ul> <li>Patient-reported outcome measurements: PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of patients reported the perception of halos, blurry vision, and glare at distance vision, respectively (Figure 2).</li> <li>Figure 2 Perception of photic phenomena 18 months postoperatively.</li> </ul>
187 188 189 190 191 192 193 194 195 196	<ul> <li>Patient-reported outcome measurements: PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of patients reported the perception of halos, blurry vision, and glare at distance vision, respectively (Figure 2).</li> <li>Figure 2 Perception of photic phenomena 18 months postoperatively.</li> <li>These percentages decreased to 2.4%, 2.4% and 4.9% for the perception of halos, blurry vision, and glare at intermediate vision, respectively (Figure 2). Analysis of this subgroup</li> </ul>
187 188 189 190 191 192 193 194 195 196 197	<ul> <li>Patient-reported outcome measurements: PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of patients reported the perception of halos, blurry vision, and glare at distance vision, respectively (Figure 2).</li> <li>Figure 2 Perception of photic phenomena 18 months postoperatively.</li> <li>These percentages decreased to 2.4%, 2.4% and 4.9% for the perception of halos, blurry vision, and glare at intermediate vision, respectively (Figure 2). Analysis of this subgroup did not reveal a significantly increased refractive error.</li> </ul>
187 188 189 190 191 192 193 194 195 196 197	<ul> <li>Patient-reported outcome measurements: PRSIQ and our own developed questionnaire were used to assess PROMs: A small percentage of patients reported postoperative perception of photic phenomena. Specifically, 9.8%, 2.4% and 9.8% of patients reported the perception of halos, blurry vision, and glare at distance vision, respectively (Figure 2).</li> <li>Figure 2 Perception of photic phenomena 18 months postoperatively.</li> <li>These percentages decreased to 2.4%, 2.4% and 4.9% for the perception of halos, blurry vision, and glare at intermediate vision, respectively (Figure 2). Analysis of this subgroup did not reveal a significantly increased refractive error.</li> </ul>

The visual quality achieved at distance and intermediate vision was subjectively graded 198 199 by the patients on a scale from 1 (very good) to 6 (very poor). This grading scale, adapted from the German school system, is widely accepted and familiar to patients. Mean 200 201 distance and intermediate visual quality satisfaction scores were 1.68 (SD: 0.72; Median: 2.00; Range: 1 to 3) and 2.05 (SD: 0.92; Median: 2.00; Range: 1 to 4), respectively. No 202 203 patient provided scores of 4 or worse when asked about satisfaction with distance and 204 intermediate visual quality. A total of 95.1% of patients reported a clearly visible dashboard when driving a car. When the dashboard was brightly illuminated, an 205 additional 97.5 % of patients reported clear visibility. 45% of patients were able to 206 207 perform screen work without spectacles, 40% had to enlarge the font and 63.4% of patients achieved spectacle-free reading when the font size was large enough. 208

Regarding the level of spectacle independence in the past 7 days, most patients did not need spectacles for distance vision (87.8%) after surgery, whereas more than half of the sample evaluated did not need them for intermediate vision (53.7%) (Figure 3A).

212

#### Figure 3.- Outcomes obtained with the PRISQ questionnaire.

214

In contrast, most patients required glasses for near vision activities (97.6%) (Figure 3A).

Furthermore, a total of 82.5% of patients did not wear glasses at any time for distance vision during the last 7 days, whereas this percentage decreased to 36.6% for intermediate vision (Figure 3B).

Concerning patient satisfaction, a total of 90.2%, 87.8%, 51.2% and 90.0% of patients
were completely, mostly or moderately satisfied with their unaided distance,
intermediate, near and overall vision, respectively (Figure 3C).

No adverse events were recorded during the follow-up, with no cases showing a
development of posterior capsular opacification (PCO) requiring YAG capsulotomy.

224

## 225 **Discussion**

To the best of our knowledge this is the first study to demonstrate excellent distance and 226 good intermediate visual acuities at long term after implantation of the ICB00. No 227 adverse events were noted. Special emphasis was placed on patients' perception: photic 228 229 phenomena were denied for distance or intermediate vision by over 90% of study participants. Furthermore, 75% of patients were completely or moderately satisfied with 230 their overall vision. This is consistent with other studies evaluating the same 231 IOL.<sup>7,10,11,17,25,26</sup> and other models of enhanced monofocal IOLs.<sup>29,30</sup> Goslings et al<sup>11</sup> 232 reported mean binocular UDVA of  $0.11 \pm 0.11$ , and UIVA of  $0.12 \pm 0.11$  at three months. 233 These visual results are slightly worse than those in our study, which could be explained 234 by a different IOL calculation formula, not specified in the publication. Giglio et al. 235 reported mean postoperative binocular UDVA, UIVA and DCIVA values of  $-0.03 \pm 0.07$ , 236  $0.17 \pm 0.12$  and  $0.13 \pm 0.11$ , in 30 eyes using the Barrett Universal II formula.<sup>7</sup> Mencucci 237 et al. also reported similar mean binocular UDVA, UIVA and DCIVA values  $(0.03 \pm 0.05)$ 238 vs.  $0.16 \pm 0.10$  vs.  $0.15 \pm 0.08$ ) in 80 eyes of 40 patients using the Holladay 1 formula for 239 axial lengths between 22.0 mm and 25.0 mm and Hoffer Q formula for axial lengths equal 240 to or less than 22.0 mm. Their axial length measurements were obtained using the IOL 241 master 500 (Carl Zeiss Meditec AG)<sup>26</sup> However, other authors have reported worse 242 UDVA and better UIVA values in eyes implanted with the ICB00 in which a micro-243 monovision approach had been applied or a trend towards a low myopic residual 244 refractive error was found. ICB00 allows for efficient restoration of distance visual 245 acuity, with enhanced intermediate visual function. 246

Furthermore, we analyzed how this functional intermediate vision was perceived by 247 248 patients. Specifically, we investigated the level of spectacle independence, perceived difficulties in daily vision-related tasks, and the perception of photic phenomena. 249 Spectacle independence was evaluated using the PRSIQ questionnaire, a validated 250 patient-reported measure assessing spectacle independence following cataract surgery.<sup>28</sup> 251 To this date and to the best of our knowledge, our study is the first to report the level of 252 253 spectacle independence achieved with the model ICB00 at 18 months or later. As is common after cataract surgery with the implantation of any conventional monofocal IOL, 254 the level of spectacle independence at distance was high: 87.8% of patients were spectacle 255 256 or contact lens free at any time of the day. However, for intermediate vision only 53.7% of patients were spectacle or contact lens free. On the other hand, when examining the 257 degree of spectacle dependence for intermediate vision, only 21.9% of patients used 258 259 spectacle correction all the time or most of the time. Regarding near vision, the level of spectacle dependence was significant, with 97.6% of patients wearing glasses for such 260 261 purposes and 75.6% of them wearing them all the time or most of the time.

Using the PRSIQ tool, Stodulka and Pracharova<sup>31</sup> investigated another IOL with an optical principle comparable to the IOL type we tested, where a special geometry creates a power gradient from the centre to the periphery. Spectacle independence with this EDOF IOL was achieved in over 80% of patients at distance and intermediate vision.

In our study, 90.2% of patients were satisfied with their uncorrected distance and 87.8% with their uncorrected intermediate vision. This confirms the ability of the enhanced monofocal IOL model ICB00 to provide satisfactory distance and intermediate visual outcomes. This is highly relevant since intermediate vision is essential for the use of computers or equivalent handheld electronic devices such as smartphones and tablets.<sup>32</sup> Regarding near vision, despite the limitations in terms of visual acuity, approximately

half of the sample reported being satisfied with their near visual functionality. This can 272 273 be explained by the visual acuity provided, which might allow a variety of near vision activities without spectacle correction. Indeed, reading activity after surgery was possible 274 275 in 14.6% of patients without any additional optical aid, and 63.4% of patients were able 276 to read without correction if font size was large enough. This finding is supported by studies by Goslings et al<sup>11</sup> and Giglio et al<sup>7</sup>, who used the validated questionnaire Catquest 277 278 9SF to investigate difficulties in performing different vision-related activities after the implantation of the ICB00 IOL and detected a trend towards improvement in Rasch-279 calibrated scores of questions about near vision. Lopes et al<sup>17</sup> evidenced significant 280 281 differences between eyes implanted with a conventional monofocal IOL and those implanted with the model ICB00 in the level of difficulty in reading newspaper print and 282 reading the prices of goods while shopping, with better outcomes in the group of eves 283 284 implanted with the enhanced monofocal IOL. In our sample, screen work could be performed postoperatively without correction by 45.0% of patients, with an additional 285 286 percentage of 40.0% of patients able to do it without problems if the font was large enough. Likewise, 95.1% of patients could clearly see the dashboard while driving a car. 287 These outcomes are consistent with those obtained with the validated questionnaire 288 289 Catquest 9SF in other studies evaluating the ICB00, in which the benefit in intermediate vision with the enhanced monofocal IOL over a conventional monofocal was consistently 290 perceived by patients.<sup>7,11,17</sup> 291

In accordance with all these PROMs, the level of visual quality graded subjectively by the patient for distance and intermediate vision was good or very good for all patients, with no patient reporting poor distance or intermediate visual quality. This was also consistent with a low percentage of patients perceiving photic phenomena, including halos, blurry vision, and glare, at distance and intermediate vision (less than 10% in all

13

cases). This aligns with optical simulations that demonstrated fewer halos with the 297 298 enhanced monofocal IOL evaluated than with the other two types of extended range of vision IOLs.<sup>33</sup> Lee and colleagues<sup>34</sup> compared the enhanced monofocal IOL evaluated in 299 300 the current study with a diffractive EDOF IOL and found that although spectacle independence was higher in the diffractive group, this was at the expense of more glare 301 and halos. Similarly, Corbelli et al<sup>16</sup> found that the enhanced monofocal IOL was not 302 303 inferior to a diffractive IOL regarding intermediate visual outcome and spectacle independence but had the advantage of less perception of halos and glare. 304

Limitations of our study include the lack of a control group with a monofocal IOL as well as data on corneal spherical aberration of the study patients. Given that neuroadaptation and habituation take 6 months and longer, this study provides important insights into patient-perceived outcomes at long term. In view of a growing array of FROF and PROF IOLs, long term data are very valuable to improve patient satisfaction and patient counselling.

In conclusion, ICB00 provides excellent levels of distance and good intermediate visual quality, leading to satisfactory levels of spectacle independence and patient satisfaction at long term. Increased long-term side-effects or increased photic phenomena were not detected. Near visual outcome, however, was more limited and varied considerably among subjects.

## 316 **References**

- 317 1.- Fernández J, Ribeiro F, Rocha-de-Lossada C, Rodríguez-Vallejo M. Functional
- 318 Classification of Intraocular Lenses Based on Defocus Curves: A Scoping Review and
- 319 Cluster Analysis. J Refract Surg. 2024;40(2):e108-e116.
- 320 2.- American National Standard for Ophthalmics. ANSI Z80.35-2018: extended depth of
- 321 focus intraocular lenses. 2018. Available at: .
- 322 3.- Fernández J, Rocha-de-Lossada C, Zamorano-Martín F, Rodríguez-Calvo-de-Mora
- 323 M, Rodríguez-Vallejo M. Positioning of enhanced monofocal intraocular lenses between
- 324 conventional monofocal and extended depth of focus lenses: a scoping review. BMC
- 325 Ophthalmol. 2023;23(1):101.
- 326 4.- Redruello-Guerrero P, Rivera-Izquierdo M, Jiménez-Gutiérrez C, Láinez-Ramos-
- Bossini AJ, Yela R, López-Marín I. Improvement of intermediate vision with new
  monofocal intraocular lenses: A systematic review and meta-analysis. Eur J Ophthalmol.
- **329** 2023;33(3):1308-1319.
- 330 5.- Wan KH, Au ACK, Kua WN, Ng ALK, Cheng GPM, Lam NM, Chow VWS.
- Enhanced Monofocal Versus Conventional Monofocal Intraocular Lens in Cataract
  Surgery: A Meta-analysis. J Refract Surg. 2022;38(8):538-546.
- 6.- Auffarth GU, Gerl M, Tsai L, Janakiraman DP, Jackson B, Alarcon A, Dick HB;
  Quantum Study Group. Clinical evaluation of a new monofocal IOL with enhanced
  intermediate function in patients with cataract. J Cataract Refract Surg. 2021 Feb
  1;47(2):184-191. doi: 10.1097/j.jcrs.000000000000399. PMID: 32932369.
- 337 7.- Giglio R, Vinciguerra AL, Presotto M, Jonak K, Rejdak R, Toro MD, Nanavaty MA,
- 338 Tognetto D. Visual outcomes and patient satisfaction after bilateral implantation of an
- enhanced monofocal intraocular lens: a single-masked prospective randomized study. Int
- 340 Ophthalmol 2024;44(1):112.

15

- 341 8.- Singh G, Sidhharthan KS, Reddy JK, Sundaram V, Thulasidas M. Comparison of
- visual outcomes in patients implanted with Tecnis Eyhance ICB00 and 1-Piece ZCB00
- monofocal intraocular lenses. Indian J Ophthalmol 2024;72(2):181-184.
- 344 9.- Negishi K, Masui S, Ayaki M, Torii H, Yotsukura E, Nishi Y. Clinical results and
- 345 factors affecting visual function in eyes implanted with an enhanced monofocal
- intraocular lens. Clin Ophthalmol 2023;17:3965-3973.
- 10.- Gigon E, Bouthour W, Panos GD, Pajic B, Massa H. Real world outcomes of the
  new Tecnis Eyhance IOL. Eur J Ophthalmol. 2023;33(3):1390-1397.
- 349 11.- Goslings O, Veraart H, van de Laar-Muskens J, Piñero DP. Clinical outcomes with
- an aspheric monofocal and a new enhanced monofocal intraocular lens with modified
- optical profile. Graefes Arch Clin Exp Ophthalmol. 2023;261(8):2315-2326.
- 352 12.- Beltraminelli, T., Rizzato, A., Toniolo, K, Galli A, Menghini M. Comparison of
- 353 visual performances of enhanced monofocal versus standard monofocal IOLs in a mini-
- monovision approach. BMC Ophthalmol 2023;23(1):170.
- 13.- Choi WK, Han HJ, Son HS, Khoramnia R, Auffarth GU, Choi CY. Clinical outcomes
- 356 of bilateral implantation of new generation monofocal IOL enhanced for intermediate
- distance and conventional monofocal IOL in a Korean population. BMC Ophthalmol2023;23(1):157.
- 14.- Garzón N, Poyales F, Albarrán-Diego C, Rico-Del-Viejo L, Pérez-Sanz L, GarcíaMontero M. Visual and optical quality of enhanced intermediate monofocal versus
  standard monofocal intraocular lens. Graefes Arch Clin Exp Ophthalmol.
  2022;260(11):3617-3625.
- 363 15.- Steinmüller LN, Greve D, Rua Amaro D, Bertelmann E, von Sonnleithner C.
  364 Analysis of higher-order aberrations in relation to the clinical outcome of an enhanced
  365 monofocal IOL. Eur J Ophthalmol 2023;33(6):2096-2105.

366 16.- Corbelli E, Iuliano L, Bandello F, Fasce F. Comparative analysis of visual outcome

- 367 with 3 intraocular lenses: monofocal, enhanced monofocal, and extended depth of focus.
- 368 J Cataract Refract Surg. 2022;48(1):67-74.
- 369 17.- Lopes D, Loureiro T, Carreira R, Rodrigues Barros S, Cardoso JN, Campos P,
- 370 Machado I, Campos N. Comparative evaluation of visual outcomes after bilateral
- 371 implantation of an advanced or conventional monofocal intraocular lens. Eur J
- 372 Ophthalmol. 2022;32(1):229-234.
- 18.- Huh J, Eom Y, Yang SK, Choi Y, Kim HM, Song JS. A comparison of clinical
  outcomes and optical performance between monofocal and new monofocal with
  enhanced intermediate function intraocular lenses: a case-control study. BMC
  Ophthalmol 2021;21(1):365.
- 19.- Ucar F, Cetinkaya S. The evaluation of a new IOL with extended depth of focus to
- increase visual acuity for intermediate distance. SN Compr Clin Med. 2021;3:22852021;
  3:2285-2291.
- 20.- Kang KH, Song MY, Kim KY, Hwang KY, Kwon YA, Koh K. Visual performance
- and optical quality after implantation of a new generation monofocal intraocular lens.
  Korean J Ophthalmol. 2021;35(2):112-119.
- 21.- Auffarth GU, Gerl M, Tsai L, Janakiraman DP, Jackson B, Alarcon A, Dick HB;
  Quantum Study Group. Clinical evaluation of a new monofocal IOL with enhanced
- intermediate function in patients with cataract. J Cataract Refract Surg. 2021;47(2):184-
- 386 191.
- 387 22.- Cinar E, Bolu H, Erbakan G, Yuce B, Aslan F, Fece M, Emre S. Vision outcomes
- with a new monofocal IOL. Int Ophthalmol. 2021;41(2):491-498.

- 23.- Unsal U, Sabur H. Comparison of new monofocal innovative and standard
  monofocal intraocular lens after phacoemulsification. Int Ophthalmol. 2021;41(1):273282.
- 392 24.- Yangzes S, Kamble N, Grewal S, Grewal SPS. Comparison of an aspheric monofocal
- intraocular lens with the new generation monofocal lens using defocus curve. Indian J
- 394 Ophthalmol. 2020;68(12):3025-3029.
- 395 25.- de Luis Eguileor B, Martínez-Indart L, Martínez Alday N, Sacristán Egüén C,
- 396 Cuadros Sánchez C. Differences in intermediate vision: monofocal intraocular lenses vs.
- monofocal extended depth of focus intraocular lenses. Arch Soc Esp Oftalmol (Engl Ed).
- 398 2020;95(11):523-527.
- 399 26.- Mencucci R, Cennamo M, Venturi D, Vignapiano R, Favuzza E. Visual outcome,
- optical quality, and patient satisfaction with a new monofocal IOL, enhanced for
  intermediate vision: preliminary results. J Cataract Refract Surg. 2020;46(3):378-387.
- 27.- Nanavaty MA, Ashena Z, Gallagher S, Borkum S, Frattaroli P, Barbon E. Visual
  acuity, wavefront aberrations, and defocus curves with an enhanced monofocal and a
  monofocal intraocular lens: a prospective, randomized study. J Refract Surg
  2022;38(1):10-20.
- 28.- Morlock R, Wirth RJ, Tally SR, Garufis C, Heichel CWD. Patient-Reported
  Spectacle Independence Questionnaire (PRSIQ): Development and Validation Am J
  Ophthalmol 2017; 178: 101-114.
- 29.- Ang RET, Stodulka P, Poyales F. Prospective randomized single-masked study of
  bilateral isofocal optic-design or monofocal intraocular lenses. Clin Ophthalmol
  2023;17:2231-2242.

- 30.- Bova A, Vita S. Clinical and Aberrometric Evaluation of a New Monofocal IOL with
  Intermediate Vision Improvement. J Ophthalmol. 2022;2022:41196982022;
  2022:4119698.
- 415 31.- Stodulka P, Pracharova Z. Evaluation of extended depth-of-focus hydrophobic
- 416 intraocular lens with an optic concept based on combination of high-order aberrations.
- 417 Ther Adv Ophthalmol 2023 Oct 3:15:25158414231200108.
- 418 32.- Ribeiro F, Cochener B, Kohnen T, Mencucci R, Katz G, Lundstrom M, Casanovas
- 419 AS, Hewlett D. Definition and clinical relevance of the concept of functional vision in
- 420 cataract surgery ESCRS Position Statement on Intermediate Vision: ESCRS Functional
- 421 Vision Working Group. J Cataract Refract Surg. 2020;46 Suppl 1:S1: S1-S3.
- 422 33.- Azor JA, Vega F, Armengol J, Millan MS. Optical assessment and expected visual
- quality of four extended range of vision intraocular lenses. J Refract Surg.
  2022;38(11):688-697.
- 425 34.- Lee JH, Moon SY, Chung HS, Park SY, Lee H, Kim JY, Tchah H. Clinical outcomes
- 426 of a monofocal intraocular lens with enhanced intermediate function compared with an
- 427 extended depth-of-focus intraocular lens. J Cataract Refract Surg. 2022;48(1):61-66.



# Figure 1



Figure 2

During the last 7 days, did you need glasses (including reading glasses or a magnifier) or contacts for ...



During the last 7 days, how often did you wear glasses (including reading glasses or a magnifier) or contacts for ...



Taking all things into account, how satisfied or dissatisfied are you with your visión when not wearing glasses (including reading glasses or a magnifier) or contacts for...

С



All of the time Most of the time Some of the time Alittle of the time None of the time

А

В

## Figure 3